Amgen (NASDAQ:AMGN) Issues Earnings Results, Beats Estimates By $0.27 EPS

Amgen (NASDAQ:AMGN - Get Free Report) posted its quarterly earnings data on Tuesday. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.04 by $0.27, Zacks reports. Amgen had a return on equity of 168.35% and a net margin of 13.00%.

Amgen Stock Up 0.1 %

NASDAQ:AMGN traded up $0.15 during mid-day trading on Tuesday, hitting $289.02. 3,209,018 shares of the company's stock were exchanged, compared to its average volume of 3,133,190. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The company has a market cap of $155.36 billion, a PE ratio of 37.01, a P/E/G ratio of 2.87 and a beta of 0.56. The business has a fifty day moving average price of $270.95 and a 200 day moving average price of $303.82. Amgen has a one year low of $253.30 and a one year high of $346.85.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.29%. This is a positive change from Amgen's previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen's dividend payout ratio (DPR) is presently 115.24%.

Analysts Set New Price Targets

AMGN has been the subject of several research reports. TD Cowen upped their target price on Amgen from $381.00 to $383.00 and gave the stock a "buy" rating in a research note on Monday, October 21st. Leerink Partners reduced their target price on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Piper Sandler lowered their price target on shares of Amgen from $344.00 to $310.00 and set an "overweight" rating for the company in a research note on Thursday, January 2nd. Jefferies Financial Group reaffirmed a "buy" rating and set a $380.00 price objective on shares of Amgen in a research note on Tuesday, November 12th. Finally, William Blair reissued an "outperform" rating on shares of Amgen in a research note on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $314.00.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.